Now, shares of OCGN stock are down roughly 20% today after negative news from the U.S. Food and Drug Administration (FDA). Specifically, Ocugen announced this morning that the FDA has declined its pediatric Emergency Use Authorization (EUA) application for Covaxin, the company’s vaccine candidate for Covid-19.
Full Answer
Should technical traders consider buying ocugen (ocgn) stock?
Apr 12, 2022 · Shares of Ocugen (NASDAQ: OCGN) are in the red this morning by about 5% following a negative development from the U.S. Food and Health Administration (FDA). Shares of OCGN stock have had a volatile...
Is ocugen stock finally showing signs of weakness?
Mar 04, 2022 · Now, shares of OCGN stock are down roughly 20% today after negative news from the U.S. Food and Drug Administration (FDA). Specifically, Ocugen announced this morning that the FDA has declined its...
Why did ocugen stock fall on Tuesday?
Apr 13, 2022 · MRNA. Ocugen ’s OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin. Ocugen ...
Is ocugen’s time in the sun coming to an end?
Nov 03, 2021 · The biotech stock was down roughly 12% in the daily session as of 11 a.m. EDT. The World Health Organization (WHO) granted Emergency Use Listing (EUL) for Bharat Biotech and Ocugen's Covaxin...
Why is OCGN stock down?
Ocugen's OCGN stock declined 3.8% on Tuesday after the FDA placed a clinical hold on a phase II/III immuno-bridging and broadening clinical study on its COVID-19 vaccine, Covaxin.5 days ago
Is OCGN good stock to buy?
Is OCUGEN Stock a good buy in 2022, according to Wall Street analysts? The consensus among 3 Wall Street analysts covering (NASDAQ: OCGN) stock is to Hold OCGN stock.
Will OCGN stock go back up?
Long-term Ocugen stock forecast 2022-2025 Algorithm-based forecasting service Wallet Investor gave a positive OCGN stock price forecast. The site predicted that the share price could climb over the next year, to $7.2 by March 2023.
What is the prediction for OCGN stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 7.00, with a high estimate of 15.00 and a low estimate of 4.00. The median estimate represents a +153.62% increase from the last price of 2.76.
Is Ocugen a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Who bought OCGN stock?
Top 10 Owners of Ocugen IncStockholderStakeShares bought / soldBlackRock Fund Advisors5.21%+18,773The Vanguard Group, Inc.4.69%-245,162Geode Capital Management LLC1.52%-82,481JPMorgan Asset Management (UK) Lt...1.49%+3,197,6156 more rows
Why did OCGN go up?
Ocugen (NASDAQ: OCGN) jumped into the coronavirus vaccine race late -- as rivals Pfizer and Moderna brought their vaccines to market. The biotech company signed a co-commercialization agreement with vaccine developer Bharat Biotech of India for that company's candidate, Covaxin.
Why did OCGN stock go up?
Shares of Ocugen ( OCGN 0.00% ) had skyrocketed by 19.1% as of 11:15 a.m. ET on Tuesday. The huge gain came after the company announced that the Food and Drug Administration (FDA) had lifted the clinical hold on its investigational new drug (IND) application for COVID-19 vaccine Covaxin.Feb 22, 2022
What is Nio price target?
The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.97, with a high estimate of 86.67 and a low estimate of 24.11.
What does Ocugen Inc do?
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
Key Points
Investors expecting a sustained bullish rally following an approval from the WHO were left disappointed.
What happened
Shares of Ocugen ( OCGN -2.40% ) are giving up ground in Wednesday's trading. The biotech stock was down roughly 12% in the daily session as of 11 a.m. EDT.
So what
Ocugen stock had made gains in premarket trading following the announcement that Covaxin had received EUL approval, but shares retreated at the opening of the normal daily session. Even with the pullback, Ocugen is up roughly 99% over the past three months and 655% year to date.
NASDAQ: OCGN
Investors appear to have been banking on the WHO's decision to drive the company's share price even higher. EUL status will make it easier for countries to import and administer the vaccine. And it means that people who have received it will be subject to fewer travel and quarantining restrictions in many countries.
Now what
Receiving EUL approval for Covaxin represents a significant milestone for Bharat Biotech and Ocugen, but it looks like expectations were already too high to power more gains for the latter company's stock. After the recent pullback, Ocugen now has a market capitalization of roughly $2.7 billion.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
Who is the CEO of Ocugen?
Ocugen CEO Shankar Musunuri and Yahoo Finance's Julie Hyman discuss a range of topics around the company's work on a COVID-19 vaccine as well as vaccine distribution and hesitancy. Motley Fool • 12 hours ago.
Is Dogecoin a dubious investment?
With a huge amount of liquidity sloshing around the market, it's no surprise that dubious investments like Dogeco in (CRYPTO: DOGE) are in vogue. The fear of a bubble popping often motivates people to invest poorly.
Who is investigating Ocugen?
Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
When is the Ocugen class action lawsuit?
(NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the "Class Period").
